UA84881C2 - Аморфный 42-эфир рапамицина и 3-гидрокси-2-(гидроксиметил)-2-метилпропионовой кислоты и фармацевтическая композиция, содержащая его - Google Patents

Аморфный 42-эфир рапамицина и 3-гидрокси-2-(гидроксиметил)-2-метилпропионовой кислоты и фармацевтическая композиция, содержащая его

Info

Publication number
UA84881C2
UA84881C2 UAA200603517A UAA200603517A UA84881C2 UA 84881 C2 UA84881 C2 UA 84881C2 UA A200603517 A UAA200603517 A UA A200603517A UA A200603517 A UAA200603517 A UA A200603517A UA 84881 C2 UA84881 C2 UA 84881C2
Authority
UA
Ukraine
Prior art keywords
amorphous form
rapamycin
hydroxymethyl
hydroxy
ester
Prior art date
Application number
UAA200603517A
Other languages
English (en)
Ukrainian (uk)
Inventor
Эрик Дж. Бенджамин
Мухаммад Ашраф
Ашвінкумар Джаін
Original Assignee
Уайт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34272870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA84881(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Уайт filed Critical Уайт
Publication of UA84881C2 publication Critical patent/UA84881C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
UAA200603517A 2003-09-03 2004-08-16 Аморфный 42-эфир рапамицина и 3-гидрокси-2-(гидроксиметил)-2-метилпропионовой кислоты и фармацевтическая композиция, содержащая его UA84881C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49978903P 2003-09-03 2003-09-03

Publications (1)

Publication Number Publication Date
UA84881C2 true UA84881C2 (ru) 2008-12-10

Family

ID=34272870

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200603517A UA84881C2 (ru) 2003-09-03 2004-08-16 Аморфный 42-эфир рапамицина и 3-гидрокси-2-(гидроксиметил)-2-метилпропионовой кислоты и фармацевтическая композиция, содержащая его

Country Status (25)

Country Link
US (2) US7271177B2 (ru)
EP (1) EP1660081A1 (ru)
JP (1) JP2007504226A (ru)
KR (1) KR20060090803A (ru)
CN (1) CN1874771A (ru)
AR (1) AR045559A1 (ru)
AU (1) AU2004270154A1 (ru)
BR (1) BRPI0414066A (ru)
CA (1) CA2536775A1 (ru)
CO (1) CO5680426A2 (ru)
CR (1) CR8293A (ru)
EC (1) ECSP066473A (ru)
GT (1) GT200400175A (ru)
IL (1) IL173786A0 (ru)
MX (1) MXPA06002123A (ru)
NO (1) NO20061048L (ru)
PA (1) PA8611201A1 (ru)
PE (1) PE20050945A1 (ru)
RU (1) RU2345999C2 (ru)
SA (1) SA04250334B1 (ru)
SG (1) SG145716A1 (ru)
TW (1) TW200510428A (ru)
UA (1) UA84881C2 (ru)
WO (1) WO2005023254A1 (ru)
ZA (1) ZA200601822B (ru)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004270154A1 (en) * 2003-09-03 2005-03-17 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same
DK1701698T3 (da) * 2004-01-08 2008-05-05 Wyeth Corp Direkte komprimerbart farmaceutisk præparat til oral indgivelse af CCI-779
US7349971B2 (en) * 2004-02-05 2008-03-25 Scenera Technologies, Llc System for transmitting data utilizing multiple communication applications simultaneously in response to user request without specifying recipient's communication information
EP1737869A1 (en) 2004-04-14 2007-01-03 Wyeth a Corporation of the State of Delaware Regiospecific synthesis of rapamycin 42-ester derivatives
JP2007534337A (ja) * 2004-04-27 2007-11-29 ワイス ラパマイシン特異的メチラーゼを用いるラパマイシンの標識
ATE483716T1 (de) * 2004-08-27 2010-10-15 Cordis Corp Lösungsmittelfreies amorphes rapamycin
US20060094744A1 (en) * 2004-09-29 2006-05-04 Maryanoff Cynthia A Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
EP1856130A1 (en) 2005-02-09 2007-11-21 Wyeth a Corporation of the State of Delaware Cci-779 polymorph and use thereof
RU2008120712A (ru) * 2005-12-07 2010-01-20 Вайет (Us) Способы получения кристаллического рапамицина и определения кристалличности соединений рапамицина при помощи дифференциальной сканирующей калориметрии
KR20080077618A (ko) * 2005-12-07 2008-08-25 와이어쓰 정제된 결정체 ｃｃｉ-779 의 제조 방법
RU2008120670A (ru) * 2005-12-07 2010-01-20 Вайет (Us) Масштабируемый способ получения 42-сложного эфира рапамицина из 42-сложного эфира рапамицина бороната
AU2006328385B2 (en) * 2005-12-21 2011-08-25 Eisai R & D Management Co., Ltd. Amorphous form of 1,2-dihydropyridine compound
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20080175887A1 (en) * 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20080234657A1 (en) * 2007-03-22 2008-09-25 Medtronic Vascular, Inc. Methods for contributing to cardiovascular treatments
JP2008305262A (ja) * 2007-06-08 2008-12-18 Konica Minolta Business Technologies Inc サーバ及びシンクライアント環境でのプリンタ紹介方法
US8852620B2 (en) 2007-07-20 2014-10-07 Medtronic Vascular, Inc. Medical devices comprising polymeric drug delivery systems with drug solubility gradients
US20090269480A1 (en) * 2008-04-24 2009-10-29 Medtronic Vascular, Inc. Supercritical Fluid Loading of Porous Medical Devices With Bioactive Agents
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
PT2365802T (pt) 2008-11-11 2017-11-14 Univ Texas Microcápsulas de rapamicina e utilização para o tratamento de cancro
US20100227799A1 (en) * 2009-03-09 2010-09-09 Medtronic Vascular, Inc. Simultaneous photodynamic therapy and photo induced polymerization
JP5637568B2 (ja) * 2009-05-12 2014-12-10 コーセプト セラピューティクス， インコーポレイテッド 固体形態および調製のためのプロセス
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
CN103298343A (zh) 2011-01-07 2013-09-11 科赛普特治疗公司 类固醇和糖皮质激素受体拮抗剂组合疗法
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US12226412B2 (en) 2012-05-25 2025-02-18 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
WO2014160328A1 (en) 2013-03-13 2014-10-02 The Board Of Regents Of The University Of Texas System Mtor inhibitors for prevention of intestinal polyp growth
US9951009B2 (en) * 2013-08-29 2018-04-24 Cadila Healthcare Limited Polymorphic form of pyrrole derivative and intermediate thereof
EP4219494B1 (en) 2013-11-25 2026-03-25 Corcept Therapeutics Incorporated Octahydro fused azadecalin glucocorticoid receptor modulators
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
AU2014373683B2 (en) 2013-12-31 2020-05-07 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
SG11201908790PA (en) 2017-03-31 2019-10-30 Corcept Therapeutics Inc Glucocorticoid receptor modulators to treat cervical cancer
EP3848065B1 (en) 2017-05-15 2023-07-26 C. R. Bard, Inc. Medical device with drug-eluting coating and intermediate layer
PT115056B (pt) * 2018-10-04 2021-12-10 Hovione Farm Sa Formas amorfas de agentes quelantes e seus métodos de preparação
JP7262581B2 (ja) 2018-11-14 2023-04-21 ルトニックス，インコーポレーテッド 改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス
WO2020132046A1 (en) 2018-12-19 2020-06-25 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
AU2019404026B2 (en) 2018-12-19 2023-06-08 Corcept Therapeutics Incorporated Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
CA3131263C (en) 2019-02-22 2024-01-02 Corcept Therapeutics Incorporated Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
JP7487228B2 (ja) 2019-04-08 2024-05-20 バード・ペリフェラル・バスキュラー・インコーポレーテッド 改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス
US11903945B2 (en) 2019-12-11 2024-02-20 Corcept Therapeutics Incorporated Methods of treating antipsychotic-induced weight gain with miricorilant
KR20230017829A (ko) 2020-05-27 2023-02-06 코어셉트 쎄라퓨틱스 인코포레이티드 글루코코르티코이드 수용체 조절제 렐라코릴란트 및 cyp2c8과 cyp3a4의 이중 기질인 파클리탁셀의 병용 투여
WO2022134033A1 (en) 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US12616698B2 (en) 2021-05-05 2026-05-05 Corcept Therapeutics Incorporated Methods for reducing liver fat and for treating fatty liver disorders
WO2024077169A1 (en) 2022-10-06 2024-04-11 Corcept Therapeutics Incorporated Formulations of glucocorticoid receptor modulators
US12433882B2 (en) 2022-10-28 2025-10-07 Corcept Therapeutics Incorporated Treatments for amyotrophic lateral sclerosis using dazucorilant
GB202415232D0 (en) 2024-10-16 2024-11-27 Nacamed As Composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
CZ292233B6 (cs) * 1995-06-09 2003-08-13 Novartis Ag Deriváty rapamycinu a jejich použití jako léčiv
FR2736550B1 (fr) 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US5989591A (en) 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
TWI256395B (en) * 1999-09-29 2006-06-11 Wyeth Corp Regioselective synthesis of rapamycin derivatives
DE60324609D1 (de) 2002-09-17 2008-12-18 Wyeth Corp GRANULIERTE FORMULIERUNG DES RAPAMYCINESTERS CCl-779
PT1658295E (pt) * 2003-08-07 2007-09-25 Wyeth Corp Síntese regiosselectiva de cci-779
AU2004270154A1 (en) * 2003-09-03 2005-03-17 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same
DK1701698T3 (da) 2004-01-08 2008-05-05 Wyeth Corp Direkte komprimerbart farmaceutisk præparat til oral indgivelse af CCI-779

Also Published As

Publication number Publication date
BRPI0414066A (pt) 2006-10-24
NO20061048L (no) 2006-05-24
GT200400175A (es) 2005-04-18
MXPA06002123A (es) 2006-05-17
EP1660081A1 (en) 2006-05-31
PE20050945A1 (es) 2005-12-14
CA2536775A1 (en) 2005-03-17
SA04250334B1 (ar) 2008-05-19
WO2005023254A1 (en) 2005-03-17
PA8611201A1 (es) 2005-05-10
US20080070950A1 (en) 2008-03-20
RU2345999C2 (ru) 2009-02-10
JP2007504226A (ja) 2007-03-01
CR8293A (es) 2006-07-14
TW200510428A (en) 2005-03-16
ZA200601822B (en) 2008-12-31
AR045559A1 (es) 2005-11-02
KR20060090803A (ko) 2006-08-16
US7446111B2 (en) 2008-11-04
US7271177B2 (en) 2007-09-18
IL173786A0 (en) 2006-07-05
CO5680426A2 (es) 2006-09-29
SG145716A1 (en) 2008-09-29
AU2004270154A1 (en) 2005-03-17
US20050049271A1 (en) 2005-03-03
CN1874771A (zh) 2006-12-06
RU2006110568A (ru) 2007-10-10
ECSP066473A (es) 2006-10-10

Similar Documents

Publication Publication Date Title
TW200510428A (en) Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions
IL166824A0 (en) Oral formulations
NO20050455L (no) Parenterale formuleringer inneholdende en rapamycinhydroksyester
MX2007005221A (es) Formas cristalinas de ascomicina y preparacion de ellas.
TW200608973A (en) Rapamycin polymorph Ⅱ and uses thereof
MXPA05012025A (es) Imidazo y tiazolopiridinas como inhibidores de cinasa jak3.
WO2005030144A3 (en) Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
WO2007044050A3 (en) 1h-imidazo[4,5-d]thieno[3,2-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
MX2009006885A (es) Derivados de pirrolo[3,2-a]piridina para inhibir la actividad de la proteina cinesina del huso.
FR2860224B1 (fr) Solide cristallise im-12 et son procede de preparation
WO2004087073A3 (en) Treatment of demyelinating conditions
EP1969939A3 (en) Nematicidal compositions
BRPI0509660A (pt) compostos de beta-carbolina de utilidade no tratamento de doenças inflamatórias
CL2007002988A1 (es) Proceso para la preparacion de un isomero individual de rapamicina 42 ester con acido 3-hidroxi-2-(hidroximetil)-2-metilpropionico (cci-779) monopegilado.
BRPI0518079A (pt) usos de um inibidor de mtor, de uma rapamicina, e de 42-éster de rapamicina com ácido 3-hidróxi-2- (hidroximetil) -2-metilpropiÈnico, composição farmacêutica, e, embalagem farmacêutica
MXPA05009934A (es) Composiciones farmaceuticas que comprenden una combinacion de rapamicina o su derivado y pimecrolimus para el tratamiento de enfermedades inflamatorias e inmunologicamente mediadas.
GB0512099D0 (en) Compounds
SG152296A1 (en) Novel process for the preparation of 5-amino-3h-thiazolo[4,5-d]pyrimidin-2- one
UA83697C2 (ru) Cci-779 для лечения лимфомы из мантийных клеток
WO2008057511A3 (en) Ascomycin and pimecrolimus having reduced levels of desmethylascomycin and 32-deoxy-32-epichloro-desmethylascomycin respectively, and methods for preparation thereof
TW200732342A (en) Process for the preparation of purified crystalline CCI-779
HK1085935A (en) Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and pharmaceutical compositions containing the same
WO2004110399A3 (en) Solvates of cefprozil
HK1071509A (en) Use of an ascomycin for the treatment of blepharitis